SG161311A1 - Novel use of spiegelmers - Google Patents

Novel use of spiegelmers

Info

Publication number
SG161311A1
SG161311A1 SG201002837-1A SG2010028371A SG161311A1 SG 161311 A1 SG161311 A1 SG 161311A1 SG 2010028371 A SG2010028371 A SG 2010028371A SG 161311 A1 SG161311 A1 SG 161311A1
Authority
SG
Singapore
Prior art keywords
spiegelmers
novel use
relates
active agent
present
Prior art date
Application number
SG201002837-1A
Other languages
English (en)
Inventor
Florian Jarosch
Christian Maasch
Sven Klussmann
Axel Vater
Dirk Eulberg
Werner Purschke
Klaus Buchner
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of SG161311A1 publication Critical patent/SG161311A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
SG201002837-1A 2005-05-04 2006-05-04 Novel use of spiegelmers SG161311A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005020874 2005-05-04

Publications (1)

Publication Number Publication Date
SG161311A1 true SG161311A1 (en) 2010-05-27

Family

ID=36928624

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201002837-1A SG161311A1 (en) 2005-05-04 2006-05-04 Novel use of spiegelmers

Country Status (11)

Country Link
US (2) US8497250B2 (enExample)
EP (2) EP1877069A2 (enExample)
JP (2) JP2008540363A (enExample)
KR (2) KR101418369B1 (enExample)
CN (2) CN104293780A (enExample)
AU (1) AU2006243334A1 (enExample)
BR (1) BRPI0610367A2 (enExample)
CA (1) CA2607185A1 (enExample)
MX (1) MX2007013760A (enExample)
SG (1) SG161311A1 (enExample)
WO (1) WO2006117217A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US20130149314A1 (en) * 2010-02-09 2013-06-13 Jörn Bullerdiek p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
WO2011131371A1 (en) 2010-04-21 2011-10-27 Noxxon Pharma Ag Lipid binding nucleic acids
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
CN102375064A (zh) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
JP2014533098A (ja) * 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト グルカゴン結合核酸
SG11201403769YA (en) * 2012-01-10 2014-07-30 Noxxon Pharma Ag Nucleic acids specifically binding cgrp
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9233119B2 (en) * 2012-09-27 2016-01-12 Miami University Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
WO2014193964A2 (en) * 2013-05-28 2014-12-04 Marsha Rosner Prognostic and predictive breast cancer signature
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
KR101755617B1 (ko) 2014-07-23 2017-07-10 한국과학기술연구원 삼차원 자기조립 핵산 나노입자 구조를 갖는 약물전달체
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EP3233174B1 (en) * 2014-12-19 2021-03-31 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
CA2985818A1 (en) 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy
EP3347051A4 (en) 2015-09-10 2019-04-24 Affigen, Inc. SEQUENCING SELECTING TUMOR THEROSTICAS
DE17829597T1 (de) * 2016-11-30 2019-12-05 Noxxon Pharma Ag Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz
US20220033813A1 (en) * 2018-09-11 2022-02-03 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
CN115997124A (zh) * 2020-04-30 2023-04-21 维兰尼迪科技有限责任公司 用于检测生物或化学实体或事件的分子导线
CN112725438B (zh) * 2021-02-05 2023-08-22 深圳市宝安区妇幼保健院 子宫内膜息肉甲基化标志物组合、检测试剂盒及应用
CN114807183B (zh) * 2021-12-06 2023-06-02 西藏自治区农牧科学院农业研究所 一种青稞矢车菊素氧甲基转移酶基因的新用途
CN118311277B (zh) * 2024-06-11 2024-12-31 北京卫未科学技术有限公司 一种用于癌症早筛和辅助诊断的试剂盒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622828A (en) * 1990-06-11 1997-04-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2)
EP1793006A3 (en) * 1993-09-08 2007-08-22 Gilead Sciences, Inc. Nucleic acid ligands and improved methods for producing the same
DE69638099D1 (de) * 1995-05-04 2010-01-28 Gilead Sciences Inc Nukleinsäureligand-komplexe
US5780611A (en) * 1995-09-15 1998-07-14 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
JP2001504448A (ja) * 1996-08-30 2001-04-03 フュルステ，イェンス，ペーター 核酸の鏡面対称選択および進化
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
JP2004510829A (ja) * 2000-10-09 2004-04-08 バイエル　アクチェンゲゼルシャフト 核酸を細胞内に転移させるための複合体
DE10118452A1 (de) * 2001-04-12 2002-10-31 Joern Bullerdiek Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse
ES2346640T4 (es) * 2001-10-26 2011-04-26 Noxxon Pharma Ag Ácido l-nucleico modificado.
WO2003051383A2 (de) * 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE10211558A1 (de) * 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
WO2003094973A1 (de) * 2002-05-08 2003-11-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mittel und verfahren zum transport von biologisch aktiven molekülen in zellen
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
KR20060015505A (ko) * 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
EP1628636A1 (de) * 2003-05-09 2006-03-01 Novosom AG Injizierbare liposomale depots zum wirkstoffdelivery
CA2526853A1 (en) * 2003-05-23 2005-03-03 Board Of Regents - The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
WO2005072703A2 (en) * 2004-01-26 2005-08-11 Control Delivery Systems, Inc. Controlled and sustained delivery of nucleic acid-based therapeutic agents
WO2006069782A2 (en) * 2004-12-27 2006-07-06 Silence Therapeutics Ag. Lipid complexes coated with peg and their use

Also Published As

Publication number Publication date
EP1877069A2 (de) 2008-01-16
EP2206501A2 (de) 2010-07-14
US8497250B2 (en) 2013-07-30
WO2006117217A3 (de) 2007-08-09
CN101217967A (zh) 2008-07-09
KR101418369B1 (ko) 2014-07-24
CN101217967B (zh) 2014-09-10
JP2013224319A (ja) 2013-10-31
US20130337049A1 (en) 2013-12-19
WO2006117217A2 (de) 2006-11-09
US20090192100A1 (en) 2009-07-30
BRPI0610367A2 (pt) 2010-06-15
CN104293780A (zh) 2015-01-21
US9074214B2 (en) 2015-07-07
AU2006243334A1 (en) 2006-11-09
KR20080009276A (ko) 2008-01-28
CA2607185A1 (en) 2006-11-09
JP2008540363A (ja) 2008-11-20
KR101418367B1 (ko) 2014-07-25
EP2206501A3 (de) 2010-09-29
KR20140042941A (ko) 2014-04-07
MX2007013760A (es) 2008-01-28
JP5766750B2 (ja) 2015-08-19

Similar Documents

Publication Publication Date Title
SG161311A1 (en) Novel use of spiegelmers
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
UA94221C2 (en) Lipocalin protein
TW200635938A (en) Fluorosurfactants
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
EA201170703A1 (ru) Производные адамантилбензамида
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
ZA200702700B (en) Diagnostic compounds
TW200942524A (en) Novel aminomethyl benzene derivatives
IL184907A0 (en) Immunologically active compositions
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
ZA200710861B (en) Uses of prostacyclin analogs
MY145179A (en) Use of tetrahydrobenzoxazines as stabilizers
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
MY157533A (en) Effervescent compositions
CY1110891T1 (el) Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
JO2549B1 (en) Fexofenadine suspension
MX2010008668A (es) Composiciones fungicidas que comprenden 3'-bromo-2,3,4,6'-tetramet oxy-2'-6-dimetilbenzofenona.
DE502006005053D1 (de) Spritzbare akustikmassen
TNSN07241A1 (en) Substituted pyrroles, compositions containing same, method for making same and use thereof
MX2007006042A (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion.
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
SG131082A1 (en) Fabp4 as marker for a toxic effect